Exercise Intervention Associated with Cognitive Improvement in Alzheimer’s Disease

• Published in: Journal of neural transplantation & plasticity Vol. 2018; no. 2018; pp. 1 - 10
• Main Authors: Zhang, Xuewen, Sheng, Jiyao, Lin, Yang, Cui, Meng Ying, Cui, R.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2018; Hindawi; John Wiley & Sons, Inc; Wiley
• Subjects: Advertising executives; Aerobics; Aged; Alzheimer Disease - psychology; Alzheimer Disease - therapy; Alzheimer's disease; Animal cognition; Brain research; Brain-derived neurotrophic factor; Cognitive ability; Cognitive Dysfunction - psychology; Cognitive Dysfunction - therapy; Dementia; Development and progression; Disease Progression; Drug dosages; Executive function; Executive Function - physiology; Exercise; Exercise - psychology; Exercise therapy; Exercise Therapy - psychology; Fitness training programs; Homocysteine; Humans; Insulin-like growth factors; Intervention; Memory; Memory, Short-Term - physiology; Neuroplasticity; Neuropsychological Tests; Older people; Physical fitness; Review; Strength training; Virtual reality
• ISSN: 2090-5904; 0792-8483; 1687-5443; 1687-5443
• DOI: 10.1155/2018/9234105

Alzheimer’s disease (AD) is a progressive neurodegenerative disease with the syndrome of cognitive and functional decline. Pharmacotherapy has always been in a dominant position for the treatment of AD. However, in most cases, drug therapy is accompanied with clinical delays when older adults have suffered from cognitive decline in episodic memory, working memory, and executive function. On the other hand, accumulating evidence suggests that exercise intervention may ameliorate the progression of cognitive impairment in aging ones while the standard strategy is lacking based on different levels of cognitive decline especially in mild cognitive impairment (MCI) and AD. MCI is the preclinical stage of AD in which neurodegeneration may be reversed via neuroplasticity. Therefore, taking exercise intervention in the early stage of MCI and healthy aging at the risk of AD could slow down the process of cognitive impairment and provide a promising cost-effective nonpharmacological therapy to dementia.